封面
市場調查報告書
商品編碼
1179909

2023-2030 年全球稀有血液學市場

Global Rare Haematology Market - 2023-2030

出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內 (2023-2030),全球罕見血液病市場規模將顯著增長。

患有罕見血液病的人佔少數。 這些疾病會影響血小板、紅細胞和白細胞,使它們難以攜帶氧氣和抵抗感染。 一些疾病,如噬血細胞性淋巴組織細胞增生症,可能是致命的。 血液疾病可以是癌性或非癌性的。 貧血是最常見的非癌性血液病。

市場動態

推動全球罕見血液病市場的主要驅動因素是某些血液病發病率的上升。 正在進行更多的臨床試驗,以促進主要參與者推進和開發新療法。

某些血液病的發病率上升是推動罕見血液病市場增長的關鍵因素。

由於多種血液疾病(包括貧血、骨髓瘤、白血病和鐮狀細胞病)的發病率不斷增加,血液學家正專注於各種檢測程序。 此外,由於需要相對快速的診斷,因此需要通過準確的診斷改進治療過程。 此外,對各種血液病診斷需求的增加也促使診斷能力的提高。

根據美國國家衛生圖書館的數據,到 2022 年,超過 20% 的 85 歲以上的人將受到影響。 貧血發生在 50-60% 的療養院人口中。 鐵質、葉酸、維生素B12缺乏等飲食缺乏是老年人貧血的主要原因,約佔三分之一。 還有三分之一的人有慢性炎症或腎功能衰竭的記錄。 並且根據 Statista 的研究,估計到 2021 年全球將有大約 234,000 名確診的血友病患者。 那時還有 90,000 多人患有 von Willebrand 病。 這兩種導致出血的遺傳疾病會阻止血液正常凝固。 由於這些因素,市場增長將在預測期內繼續獲得動力。

罕見血液病診斷的高成本預計會阻礙市場的增長。

罕見的血液學市場因價格高而面臨制約,不利的報銷政策也是阻礙市場增長的主要因素。

COVID-19 影響分析

最近幾個月,大多數行業都受到了不利影響。 這是由於全球監管機構施加的各種預防性封鎖和其他限制嚴重擾亂了他們的供應鍊和製造流程。 市場也是如此。

此外,由於許多人的總體經濟狀況受到大流行的嚴重影響,人們更有可能從預算中削減非必要支出,從而減少消費需求。我在這裡。 預計這些因素將在預測期內對市場產生不利影響。 不過,全球罕見病血液檢測市場有望在相關政府機構解除藥品限制後復蘇。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 某些血液病的發病率增加
      • 正在進行更多臨床試驗以加快進展
    • 約束因素
      • 飆升的診斷成本預計會阻礙市場增長。
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章(按產品類別)

  • 重組因子
  • 血漿衍生因子
  • 延長半衰期

第八章按功效與作用

  • 罕見血癌
  • 血小板相關疾病
  • 血漿疾病
  • 骨髓增生性疾病
  • 遺傳性血液病

第 9 章患者年齡組

  • 兒科 (0-17)
  • 成人(18 歲以上)

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第12章公司簡介

  • 諾華公司
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Bristol-Myers Squibb Company
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd
  • Emmaus Medical, Inc.
  • Pfizer Inc.
  • Bayer AG
  • Amgen Inc
  • CSL Behring LLC.
  • Vega Therapeutics Inc

第13章 DataM

簡介目錄
Product Code: DMPH15

Market Overview

The global rare haematology market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

A small number of individuals have rare blood diseases. They can impact platelets, red blood cells, or white blood cells, which makes it challenging to transfer oxygen and fight infections. A few conditions, such hemophagocytic lymphohistiocytosis, can be fatal. Cancerous and non-cancerous blood diseases both exist. The most prevalent non-cancerous blood condition is anemia.

Market Dynamics

The major factors driving the global rare haematology market are the rising incidence of certain blood diseases. More clinical trials are being conducted to promote progress and developing of novel treatments by the key players.

The rising incidence of certain blood diseases is the prime factor driving the growth of the rare haematology market.

Hematologists are concentrating on various detection procedures due to the rising occurrence of numerous blood disorders such as anemia, myeloma, leukemia, and sickle cell anemia. Hematologists are looking for improved treatment processes through accurate diagnosis processes as the requirement for conducting relatively rapid diagnosis processes is becoming the order of the day. Hematologists' attention to improving their diagnostic abilities has been further prompted by the increased necessity to identify various blood disorders.

More than 20% of those over the age of 85 are affected, according to the National Library of Health, U.S., 2022. In the population of nursing homes, anemia occurs 50% to 60% of the time. A dietary deficit, such as a lack of iron, folate, or vitamin B12, is the main cause of anemia in the elderly, accounting for about one-third of patients. There is proof of chronic inflammation or renal failure in another third of the individuals. And Statista research estimates that around 234 thousand hemophilia cases will be confirmed globally in 2021. And 90,000 more persons had von Willebrand disease at that time. These two hereditary illnesses that cause bleeding prevent blood from clotting correctly. Due to these factors, the market's growth will continue to pick up steam during the forecast timeframe.

Due to the high price of diagnosing rare haematology is expected to hamper the market's growth.

The rare haematology market will face limitations due to the high price of the disease, and unfavorable reimbursement policies are also a key factor hindering the growth of the market.

COVID-19 Impact Analysis

The majority of industries have had unfavorable effects in recent months. This can be ascribed to major interruptions in their supply chains and manufacturing processes due to global regulatory agencies' various precautionary lockdowns and other restrictions. The market is no different.

Additionally, consumer demand has decreased as people have become more motivated to cut non-essential spending from their budgets as the general economic situation of most people has been badly impacted by the pandamic. The above factors are anticipated throughout the forecast period to impact the market negatively. However, the global rare hematology market is anticipated to rebound after the relevant governing bodies start pharmaceuticals lift such imposed lockdowns.

Segment Analysis

The adults segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The blood clots incorrectly as a result of hemophilia, an inherited bleeding disorder. Both spontaneous bleeding and bleeding after an accident or surgery may come from this. Hemophilia A primarily affects men, while it can also affect women. Hemophilia A affects about 1 in 5,000 newborns. A severe type of hemophilia A affects about 60% of those who suffer from it.

According to projections made by the American Cancer Society, there will be roughly 20,050 new cases of acute myeloid leukemia (AML) in the state in 2022, most of which will affect adults. AML will cause 11,540 deaths, almost all of which will be in adults.

According to the Indian Express News article from April 2019, approximately 80% of Indians with dangerous blood illness are believed to go undiagnosed since there aren't adequate diagnostic facilities in remote locations, despite advancements in medical technology for hemophilia treatment. Ahead of World Hemophilia Day on April 17, physicians projected that India, with about 200,000 cases, has the second-highest population of individuals with hemophilia. This chronic bleeding illness prevents blood from clotting. This opens up a large market opportunity and will spur growth in the upcoming years.

Geographical Analysis

North America holds the largest market share in the global rare haematology market.

North America dominates the global Rare Haematology market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively moderate pace during the forecast period. Due to the growing elderly population and rising prevalence of rare blood disorders, the North American market for rare hematological disorders would rise. Additionally, the industry will experience a rapid expansion in the coming years due to the major pharmaceutical companies' research initiatives to create new drugs.

Numerous Americans, including millions of people, are carriers of genes that can lead to blood diseases like sickle cell disease and hemophilia, according to the Office of Disease Prevention and Health Promotion's 2019 report. The goal of Healthy People 2030 is to improve the health and standard of living of people with blood diseases.

In the U.S., sickle cell disease, a blood condition, affects more than 100,000 people. Blood transfusions can help avoid and treat problems, and interventions, such as plans to use more hydroxyurea, can improve the health outcomes of patients with sickle cell disease. The regional expansion will be further aided by improved healthcare infrastructure, rising healthcare spending, and helpful government efforts. For instance, scientists funded by the National Heart, Lung, and Blood Institute (NHLBI) in June 2021 discovered life-saving therapies for hemophilia patients and are currently working on gene therapy options to treat the condition.

Competitive Landscape

The Rare Haematology market is moderately competitive with local and global companies' presence Novartis, Bristol-Myers Squibb Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emmaus Medical, Inc., Pfizer Inc., Bayer AG, Amgen Inc, CSL Behring LLC and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in December 2022, The 64th American Society of Hematology (ASH) Annual Meeting saw the introduction and public presentation of VGA039, a first-in-class antibody treatment developed by Vega Therapeutics, Inc., a clinical stage biotechnology company.

Novartis AG.

Overview: A healthcare company named Novartis AG (Novartis) specializes in developing, producing, and marketing prescription and over-the-counter medicines and eye care products. It offers medicines for infections, cancer, cardiovascular disease, dermatological issues, neurological disorders, ophthalmic and respiratory illnesses, and cancer. Through Sandoz, the business provides biosimilars and generic medications. Through The Novartis Institutes for BioMedical Research, Novartis conducts research in several illness areas (NIBR).

Product Portfolio:

Novartis drug Promacta: PROMACTA is indicated in combination with standard immunosuppressive therapy (IST) for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia. PROMACTA is indicated for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

Theglobal Rare Haematology market report would provide access to approx.: 45 + market data table, 40 + figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising incidence of certain blood diseases
      • 4.1.1.2. More clinical trials are being conducted to promote progress
    • 4.1.2. Restraints:
      • 4.1.2.1. Due to the high price of diagnosing is expected to hamper the market's growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
    • 7.1.2. Market Attractiveness Index, By Product Class
  • 7.2. Recombinant factor
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Plasma-derived factors
  • 7.4. Extended Half-Life

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Rare blood cancers
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Platelet based disorders
  • 8.4. Plasma disorders
  • 8.5. Myeloproliferative disorders
  • 8.6. Genetic hematology disorders

9. By Patient Age-Group

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group
    • 9.1.2. Market Attractiveness Index, By Patient Age-Group
  • 9.2. Pediatrics (0-17)
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Adults (18+)

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Novartis AG
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bristol-Myers Squibb Company
  • 12.3. Novo Nordisk A/S
  • 12.4. F. Hoffmann-La Roche Ltd
  • 12.5. Emmaus Medical, Inc.
  • 12.6. Pfizer Inc.
  • 12.7. Bayer AG
  • 12.8. Amgen Inc
  • 12.9. CSL Behring LLC.
  • 12.10. Vega Therapeutics Inc

LIST NOT EXHAUSTIVE

13. Global Rare Haematology Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us